This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abacavir and lamivudine (Mylan)
Drug Names(s): abacavir and lamivudine
Mylan's version of abacavir/lamivudine is the first version with scoring to allow for dose adjustment and flavoring. Available dosages are 120/60mg and 60/30mg compared to Epzicom's 600/300mg.
Epzicom (Kivexa in Europe) combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), Epivir (Lamivudine, 3TC) and Ziagen (Abacavir sulfate, ABC) for use in combination with other antiretroviral drugs.
Teva and Mylan
In April 2015, Teva proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock.
In April 2015, Mylan announced that its Board of Directors has unanimously rejected the unsolicited expression of interest from Teva Pharmaceutical to acquire Mylan. After a comprehensive review conducted in consultation with its financial and legal advisors, the Mylan Board concluded the approach did not meet any of the key criteria that would cause the Mylan Board to depart from the Company's standalone strategy, and consider engaging in discussions to sell the Company.
Teva reiterated its commitment to its proposed combination with Mylan. As previously announced, Teva has proposed to acquire Mylan for $82.00 per share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Tevas...See full deal structure in Biomedtracker
Abacavir and lamivudine (Mylan) News
Additional information available to subscribers only: